Evonile Pharma Receives In-Principle BSE Approval for ₹9,000 Million Rights Issue
Novartis India Ltd · Intimation · 01 Nov 2026, 7:49 pm
Evonile Pharma Receives In-Principle BSE Approval for ₹9,000 Million Rights Issue Evonile Pharma Limited (formerly Novartis India Limited) received in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly paid-up equity shares aggregating up to ₹9,000.00 million. The company scheduled meetings of its Board of Directors and Rights Issue Committee on 4th Nov'26 to consider and approve the Letter of Offer and finalize key terms, including the issue price, rights entitlement ratio, and record date.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
